Tolerance to Opioid‐Induced Respiratory Depression in Chronic High‐Dose Opioid Users: A Model‐Based Comparison With Opioid‐Naïve Individuals. Issue 3 (5th October 2020)
- Record Type:
- Journal Article
- Title:
- Tolerance to Opioid‐Induced Respiratory Depression in Chronic High‐Dose Opioid Users: A Model‐Based Comparison With Opioid‐Naïve Individuals. Issue 3 (5th October 2020)
- Main Title:
- Tolerance to Opioid‐Induced Respiratory Depression in Chronic High‐Dose Opioid Users: A Model‐Based Comparison With Opioid‐Naïve Individuals
- Authors:
- Algera, Marijke Hyke
Olofsen, Erik
Moss, Laurence
Dobbins, Robert L.
Niesters, Marieke
van Velzen, Monique
Groeneveld, Geert Jan
Heuberger, Jules
Laffont, Celine M.
Dahan, Albert - Abstract:
- Abstract : Chronic opioid consumption is associated with addiction, physical dependence, and tolerance. Tolerance results in dose escalation to maintain the desired opioid effect. Intake of high‐dose or potent opioids may cause life‐threatening respiratory depression, an effect that may be reduced by tolerance. We performed a pharmacokinetic‐pharmacodynamic analysis of the respiratory effects of fentanyl in chronic opioid users and opioid‐naïve subjects to quantify tolerance to respiratory depression. Fourteen opioid‐naïve individuals and eight chronic opioid users received escalating doses of intravenous fentanyl (opioid‐naïve subjects: 75–350 µg/70 kg; chronic users: 250–700 µg/70 kg). Isohypercapnic ventilation was measured and the fentanyl plasma concentration‐ventilation data were analyzed using nonlinear mixed‐effects modeling. Apneic events occurred in opioid‐naïve subjects after a cumulative fentanyl dose (per 70 kg) of 225 ( n = 3) and 475 µg ( n = 6), and in 7 chronic opioid users after a cumulative dose of 600 ( n = 2), 1, 100 ( n = 2), and 1, 800 µg ( n = 3). The time course of fentanyl's respiratory depressant effect was characterized using a biophase equilibration model in combination with an inhibitory maximum effect (Emax ) model. Differences in tolerance between populations were successfully modeled. The effect‐site concentration causing 50% ventilatory depression, was 0.42 ± 0.07 ng/mL in opioid‐naïve subjects and 1.82 ± 0.39 ng/mL in chronic opioidAbstract : Chronic opioid consumption is associated with addiction, physical dependence, and tolerance. Tolerance results in dose escalation to maintain the desired opioid effect. Intake of high‐dose or potent opioids may cause life‐threatening respiratory depression, an effect that may be reduced by tolerance. We performed a pharmacokinetic‐pharmacodynamic analysis of the respiratory effects of fentanyl in chronic opioid users and opioid‐naïve subjects to quantify tolerance to respiratory depression. Fourteen opioid‐naïve individuals and eight chronic opioid users received escalating doses of intravenous fentanyl (opioid‐naïve subjects: 75–350 µg/70 kg; chronic users: 250–700 µg/70 kg). Isohypercapnic ventilation was measured and the fentanyl plasma concentration‐ventilation data were analyzed using nonlinear mixed‐effects modeling. Apneic events occurred in opioid‐naïve subjects after a cumulative fentanyl dose (per 70 kg) of 225 ( n = 3) and 475 µg ( n = 6), and in 7 chronic opioid users after a cumulative dose of 600 ( n = 2), 1, 100 ( n = 2), and 1, 800 µg ( n = 3). The time course of fentanyl's respiratory depressant effect was characterized using a biophase equilibration model in combination with an inhibitory maximum effect (Emax ) model. Differences in tolerance between populations were successfully modeled. The effect‐site concentration causing 50% ventilatory depression, was 0.42 ± 0.07 ng/mL in opioid‐naïve subjects and 1.82 ± 0.39 ng/mL in chronic opioid users, indicative of a 4.3‐fold sensitivity difference. Despite higher tolerance to fentanyl‐induced respiratory depression, apnea still occurred in the opioid‐tolerant population indicative of the potential danger of high‐dose opioids in causing life‐threatening respiratory depression in all individuals, opioid‐naïve and opioid‐tolerant. … (more)
- Is Part Of:
- Clinical pharmacology & therapeutics. Volume 109:Issue 3(2021)
- Journal:
- Clinical pharmacology & therapeutics
- Issue:
- Volume 109:Issue 3(2021)
- Issue Display:
- Volume 109, Issue 3 (2021)
- Year:
- 2021
- Volume:
- 109
- Issue:
- 3
- Issue Sort Value:
- 2021-0109-0003-0000
- Page Start:
- 637
- Page End:
- 645
- Publication Date:
- 2020-10-05
- Subjects:
- Pharmacology -- Periodicals
Therapeutics -- Periodicals
615.5 - Journal URLs:
- http://www.nature.com/clpt/index.html ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1532-6535 ↗
http://www.nature.com/ ↗
http://firstsearch.oclc.org ↗
http://www.mosby.com/cpt ↗
http://www.sciencedirect.com/science/journal/00099236 ↗
http://www2.us.elsevierhealth.com/scripts/om.dll/serve?action=searchDB&searchdbfor=home&id=cp ↗ - DOI:
- 10.1002/cpt.2027 ↗
- Languages:
- English
- ISSNs:
- 0009-9236
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.330000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22000.xml